Pfizer tests new obesity drug in major Weight-Loss trial

NCT ID NCT06717425

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

Summary

This study tested a new weight-loss medicine called PF-07976016 to see if it's safe and effective for adults with obesity. Researchers compared people taking the medicine to those taking a placebo (inactive pill) to measure changes in body weight and side effects. The trial involved 263 adults and aimed to find the right dose for future studies.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AMR Clinical

Norman, Oklahoma, 73069, United States
Accellacare - Wilmington

Wilmington, North Carolina, 28401, United States
Anaheim Clinical Trials, LLC

Anaheim, California, 92801, United States
Artemis Institute for Clinical Research

San Diego, California, 92103, United States
Canadian Phase Onward

Toronto, Ontario, M3J 0K2, Canada
Capital Area Research, LLC

Camp Hill, Pennsylvania, 17011, United States
Centrum Badan Klinicznych PI-House sp. z o.o.

Gdansk, Pomeranian Voivodeship, 80-546, Poland
Centrum Medyczne Pratia Gdynia

Gdynia, Pomeranian Voivodeship, 81-338, Poland
Centrum Zdrowia Metabolicznego Pawel Bogdanski

Poznan, Greater Poland Voivodeship, 60-589, Poland
Chrysalis Clinical Research

St. George, Utah, 84790, United States
Clinical & Translational Research Center

Aurora, Colorado, 80045, United States
Consano Clinical Research, LLC

Shavano Park, Texas, 78231, United States
Cornerstone Nutrition and Diabetes

Norman, Oklahoma, 73069, United States
Cotton O'Neil Diabetes & Endocrinology

Topeka, Kansas, 66606, United States
Dawson Clinical Research Inc.

Guelph, Ontario, N1H 1B1, Canada
East-West Medical Research Institute

Honolulu, Hawaii, 96814, United States
Ekamed

Lublin, Lublin Voivodeship, 20-718, Poland
Elligo Clinical Research Center

Austin, Texas, 78704, United States
L-MARC Research Center

Louisville, Kentucky, 40213, United States
Medicome Sp. z o. o.

Oświęcim, Lesser Poland Voivodeship, 32-600, Poland
Milestone Research Inc.

London, Ontario, N5W 6A2, Canada
New Horizon Research Center

Miami, Florida, 33165, United States
Ocean West Research Clinic

Surrey, British Columbia, V3Z 2N6, Canada
Pennington Biomedical Research Center

Baton Rouge, Louisiana, 70808, United States
Renstar Medical Research

Ocala, Florida, 34470, United States
Renstar Medical Research

Ocala, Florida, 34471, United States
Rochester Clinical Research, LLC

Rochester, New York, 14609, United States
Rophe Adult and Pediatric Medicine/SKYCRNG

Union City, Georgia, 30291, United States
Selma Medical Associates

Winchester, Virginia, 22601, United States
Southwest Internal Medicine, PC

St. George, Utah, 84790, United States
St Johns Center for Clinical Research

Saint Augustine, Florida, 32086, United States
StudyMetrix Research

City of Saint Peters, Missouri, 63303, United States
Texas Diabetes & Endocrinology, P.A.

Austin, Texas, 78749, United States
The Wharton Medical Clinic Clinical Trials Inc.

Hamilton, Ontario, L8L 5G8, Canada
UT Southwestern Medical Center

Dallas, Texas, 75390, United States
University of Colorado Anschutz Medical Campus

Aurora, Colorado, 80045, United States
Velocity Clinical Research, Dallas

Dallas, Texas, 75230, United States
Westside Center for Clinical Research

Jacksonville, Florida, 32205, United States

Conditions

Explore the condition pages connected to this study.

OBESITY